Anti-addiction drug ibogaine inhibits voltage-gated ionic currents: A study to assess the drug's cardiac ion channel profile

Toxicology and Applied Pharmacology

Volumn 273, Issue 2, 2013, Pages 259-268

  Koenig, Xaver ^a   Kovar, Michael ^a   Rubi, Lena ^a   Mike, Agnes K ^a   Lukacs, Peter ^a   Gawali, Vaibhavkumar S ^a   Todt, Hannes ^a   Hilber, Karlheinz ^a   Sandtner, Walter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

18 Methoxycoronaridine; Anti addiction drug; HERG potassium channels; Ibogaine; QT interval prolongation; Voltage gated ion channels

Indexed keywords

18 METHOXYCORONARIDINE; CALCIUM CHANNEL CAV1.2; IBOGAINE; ION CHANNEL; POTASSIUM CHANNEL HERG; SODIUM CHANNEL NAV1.5; UNCLASSIFIED DRUG;

ACTION POTENTIAL; ANIMAL CELL; ARTICLE; COMPUTER MODEL; COMPUTER SIMULATION; CONCENTRATION RESPONSE; DRUG POTENCY; DRUG SAFETY; ELECTROCARDIOGRAM; EXPERIMENTAL GUINEA PIG; FEMALE; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HEART REPOLARIZATION; HETEROLOGOUS EXPRESSION; IC 50; IN VITRO STUDY; ION CURRENT; NONHUMAN; PLASMA PROTEIN BINDING; QT INTERVAL; STEADY STATE;

18-MC; 18-METHOXYCORONARIDINE; ACTION POTENTIAL; ANTI-ADDICTION DRUG; AP; HERG; HERG POTASSIUM CHANNELS; HUMAN ETHER-À-GO-GO-RELATED GENE; IBOGAINE; QT INTERVAL PROLONGATION; VOLTAGE-GATED ION CHANNELS;

ACTION POTENTIALS; ANIMALS; BEHAVIOR, ADDICTIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; GUINEA PIGS; HUMANS; IBOGAINE; ION CHANNELS; MYOCYTES, CARDIAC; POTASSIUM CHANNEL BLOCKERS;

CAVIA;

EID: 84888203455     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.05.012     Document Type: Article

References (45)

1. Alper K.R. Ibogaine: a review. Alkaloids Chem. Biol. 2001, 56:1-38.
2. Alper K.R., Lotsof H.S., Kaplan C.D. The ibogaine medical subculture. J. Ethnopharmacol. 2008, 115:9-24.
3. Alper K.R., Stajic M., Gill J.R. Fatalities temporally associated with the ingestion of ibogaine. J. Forensic Sci. 2012, 57:398-412.
4. Benwell M.E., Holtom P.E., Moran R.J., Balfour D.J. Neurochemical and behavioural interactions between ibogaine and nicotine in the rat. Br. J. Pharmacol. 1996, 117:743-749.
5. Binienda Z., Beaudoin M.A., Thorn B.T., Prapurna D.R., Johnson J.R., Fogle C.M., Slikker W., Ali S.F. Alteration of electroencephalogram and monoamine concentrations in rat brain following ibogaine treatment. Ann. N. Y. Acad. Sci. 1998, 844:265-273.
6. Chen J., Zou A., Splawski I., Keating M.T., Sanguinetti M.C. Long QT syndrome-associated mutations in the Per-Arnt-Sim (PAS) domain of HERG potassium channels accelerate channel deactivation. J. Biol. Chem. 1999, 274:10113-10118.
7. Davie C., Pierre-Valentin J., Pollard C., Standen N., Mitcheson J., Alexander P., Thong B. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel. J. Cardiovasc. Electrophysiol. 2004, 15:1302-1309.
8. Donnelly J.R. The need for ibogaine in drug and alcohol addiction treatment. J. Leg. Med. 2011, 32:93-114.
9. Glick S.D., Maisonneuve I.S. Mechanisms of antiaddictive actions of ibogaine. Ann. N. Y. Acad. Sci. 1998, 844:214-226.
10. Glick S.D., Maisonneuve I.M. Development of novel medications for drug addiction. The legacy of an African shrub. Ann. N. Y. Acad. Sci. 2000, 909:88-103.
11. Glick S.D., Kuehne M.E., Maisonneuve I.M., Bandarage U.K., Molinari H.H. 18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats. Brain Res. 1996, 719:29-35.
12. Glick S.D., Maisonneuve I.M., Szumlinski K.K. 18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action. Ann. N. Y. Acad. Sci. 2000, 914:369-386.
13. Glick S.D., Maisonneuve I.M., Szumlinski K.K. Mechanisms of action of ibogaine: relevance to putative therapeutic effects and development of a safer iboga alkaloid congener. Alkaloids Chem. Biol. 2001, 56:39-53.
14. Glick S.D., Sell E.M., McCallum S.E., Maisonneuve I.M. Brain regions mediating alpha3beta4 nicotinic antagonist effects of 18-MC on nicotine self-administration. Eur. J. Pharmacol. 2011, 669:71-75.
15. Grace A.A., Camm A.J. Voltage-gated calcium-channels and antiarrhythmic drug action. Cardiovasc. Res. 2000, 45:43-51.
16. Guo J., Massaeli H., Xu J., Jia Z., Wigle J.T., Mesaeli N., Zhang S. Extracellular K+ concentration controls cell surface density of IKr in rabbit hearts and of the HERG channel in human cell lines. J. Clin. Invest. 2009, 119:2745-2757.
17. Hoelen D.W., Spiering W., Valk G.D. Long-QT syndrome induced by the antiaddiction drug ibogaine. N. Engl. J. Med. 2009, 360:308-309.
18. Koenig X., Dysek S., Kimbacher S., Mike A.K., Cervenka R., Lukacs P., Nagl K., Dang X.B., Todt H., Bittner R.E., Hilber K. Voltage-gated ion channel dysfunction precedes cardiomyopathy development in the dystrophic heart. PLoS One 2011, 6:e20300.
19. Koenig X., Kovar M., Boehm S., Sandtner W., Hilber K. Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk. Addict. Biol. 2012, (Epub ahead of print). 10.1111/j.1369-1600.2012.00447.x.
20. Kontrimaviciute V., Breton H., Mathieu O., Mathieu-Daude J.C., Bressolle F.M. Liquid chromatography-electrospray mass spectrometry determination of ibogaine and noribogaine in human plasma and whole blood. Application to a poisoning involving Tabernanthe iboga root. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2006, 843:131-141.
21. Lloyd C.M., Lawson J.R., Hunter P.J., Nielsen P.F. The CellML model repository. Bioinformatics 2008, 24:2122-2123.
22. Maas U., Strubelt S. Fatalities after taking ibogaine in addiction treatment could be related to sudden cardiac death caused by autonomic dysfunction. Med. Hypotheses 2006, 67:960-964.
23. Maciulaitis R., Kontrimaviciute V., Bressolle F.M., Briedis V. Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review. Hum. Exp. Toxicol. 2008, 27:181-194.
24. Maisonneuve I.M., Keller R.W., Glick S.D. Interactions between ibogaine, a potential anti-addictive agent, and morphine: an in vivo microdialysis study. Eur. J. Pharmacol. 1991, 199:35-42.
25. Mash D.C., Kovera C.A., Buck B.E., Norenberg M.D., Shapshak P., Hearn W.L., Sanchez-Ramos J. Medication development of ibogaine as a pharmacotherapy for drug dependence. Ann. N. Y. Acad. Sci. 1998, 844:274-292.
26. Mash D.C., Kovera C.A., Pablo J., Tyndale R.F., Ervin F.D., Williams I.C., Singleton E.G., Mayor M. Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Ann. N. Y. Acad. Sci. 2000, 914:394-401.
27. Mille M., Koenig X., Zebedin E., Uhrin P., Cervenka R., Todt H., Hilber K. Sodium current properties of primary skeletal myocytes and cardiomyocytes derived from different mouse strains. Pflugers Arch. 2009, 457:1023-1033.
28. Molinari H.H., Maisonneuve I.M., Glick S.D. Ibogaine neurotoxicity: a re-evaluation. Brain Res. 1996, 737:255-262.
29. O'Hara T., Rudy Y. Quantitative comparison of cardiac ventricular myocyte electrophysiology and response to drugs in human and nonhuman species. Am. J. Physiol. Heart Circ. Physiol. 2012, 302:H1023-H1030.
30. O'Hearn E., Molliver M.E. Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline. Neuroscience 1993, 55:303-310.
31. Paling F.P., Andrews L.M., Valk G.D., Blom H.J. Life-threatening complications of ibogaine: three case reports. Neth. J. Med. 2012, 70:422-424.
32. Perry M., Sanguinetti M., Mitcheson J. Revealing the structural basis of action of hERG potassium channel activators and blockers. J. Physiol. 2010, 588:3157-3167.
33. Pleskovic A., Gorjup V., Brvar M., Kozelj G. Ibogaine-associated ventricular tachyarrhythmias. Clin. Toxicol. (Phila.) 2012, 50:157.
34. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., Siegl P.K., Strang I., Sullivan A.T., Wallis R., Camm A.J., Hammond T.G. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 2003, 58:32-45.
35. Sanguinetti M.C., Jurkiewicz N.K. Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents. J. Gen. Physiol. 1990, 96:195-215.
36. Sanguinetti M.C., Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006, 440:463-469.
37. Soldatov N.M., Zhenochin S., AlBanna B., Abernethy D.R., Morad M. New molecular determinant for inactivation of the human l-type alpha1C Ca2+ channel. J. Membr. Biol. 2000, 177:129-135.
38. ten Tusscher K.H., Noble D., Noble P.J., Panfilov A.V. A model for human ventricular tissue. Am. J. Physiol. Heart Circ. Physiol. 2004, 286:H1573-H1589.
39. Terrenoire C., Simhaee D., Kass R.S. Role of sodium channels in propagation in heart muscle: how subtle genetic alterations result in major arrhythmic disorders. J. Cardiovasc. Electrophysiol. 2007, 18:900-905.
40. Vastag B. Addiction research. Ibogaine therapy: a 'vast, uncontrolled experiment'. Science 2005, 308:345-346.
41. Xu Z., Chang L.W., Slikker W., Ali S.F., Rountree R.L., Scallet A.C. A dose-response study of ibogaine-induced neuropathology in the rat cerebellum. Toxicol. Sci. 2000, 57:95-101.
42. Yang T., Roden D.M. Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. Circulation 1996, 93:407-411.
43. Yao X., Anderson D.L., Ross S.A., Lang D.G., Desai B.Z., Cooper D.C., Wheelan P., McIntyre M.S., Bergquist M.L., MacKenzie K.I., Becherer J.D., Hashim M.A. Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model. Br. J. Pharmacol. 2008, 154:1446-1456.
44. Zebedin E., Koenig X., Radenkovic M., Pankevych H., Todt H., Freissmuth M., Hilber K. Effects of duramycin on cardiac voltage-gated ion channels. Naunyn Schmiedebergs Arch. Pharmacol. 2008, 377:87-100.
45. Zicha S., Moss I., Allen B., Varro A., Papp J., Dumaine R., Antzelevich C., Nattel S. Molecular basis of species-specific expression of repolarizing K+ currents in the heart. Am. J. Physiol. Heart Circ. Physiol. 2003, 285:H1641-H1649.